Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Secondary (Hypogodotropic) Hypogodism - Overview
Secondary (Hypogodotropic) Hypogodism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Secondary (Hypogodotropic) Hypogodism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Secondary (Hypogodotropic) Hypogodism - Companies Involved in Therapeutics Development
Allergan Ltd
Beijing Fogangren Bio-Pharm Tech Co Ltd
Diurl Group Plc
IASO BioMed Inc
Marius Pharmaceuticals LLC
Merck & Co Inc
Mereo Biopharma Group Plc
NHTherapeutics Inc
Veru Inc
Secondary (Hypogodotropic) Hypogodism - Drug Profiles
corifollitropin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IAS-167A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leflutrozole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rifene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VERU-722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Secondary (Hypogodotropic) Hypogodism - Dormant Projects
Secondary (Hypogodotropic) Hypogodism - Discontinued Products
Secondary (Hypogodotropic) Hypogodism - Product Development Milestones
Featured News & Press Releases
Jul 30, 2020: Diurl Group announces positive DITEST regulatory meeting with US FDA
May 21, 2020: Marius Pharmaceuticals announces issuance of two key patents protecting its proprietary oral testosterone therapy
Jan 15, 2019: Mereo BioPharma: BGS-649 Phase 2b data to be Presented at ENDO 2019
Dec 17, 2018: Mereo BioPharma announces positive results from the safety extension study to the phase 2b clinical trial of BGS-649 for the treatment of hypogodotropic hypogodism in obese men
Sep 05, 2017: Completion of Patient Enrolment in Phase 2b dose-confirmation study of BGS-649 for the treatment of hypogodotropic hypogodism
Mar 07, 2017: Mereo BioPharma Group: Positive recommendation for BGS-649 Phase 2b trial following planned IDMC interim alysis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020


List of Tables


Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Allergan Ltd, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Beijing Fogangren Bio-Pharm Tech Co Ltd, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Diurnal Group Plc, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by IASO BioMed Inc, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Marius Pharmaceuticals LLC, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Merck & Co Inc, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by NHTherapeutics Inc, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Veru Inc, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products, H2 2020